lamotrigine, 300 mg/day
LAM30055
Phase 3 small_molecule completed
Quick answer
lamotrigine, 300 mg/day for Epilepsy, Partial is a Phase 3 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Epilepsy, Partial
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed